Prescott Group Capital Management L.L.C. acquired a new stake in Bausch Health Companies Inc. (NYSE:BHC – Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 71,316 shares of the company’s stock, valued at approximately $571,000.
Several other large investors have also recently made changes to their positions in the business. Public Sector Pension Investment Board increased its holdings in Bausch Health Companies by 7.3% during the first quarter. Public Sector Pension Investment Board now owns 602,663 shares of the company’s stock worth $4,876,000 after buying an additional 41,211 shares during the last quarter. Mackenzie Financial Corp raised its holdings in shares of Bausch Health Companies by 4.2% in the 2nd quarter. Mackenzie Financial Corp now owns 1,138,717 shares of the company’s stock worth $9,110,000 after purchasing an additional 45,768 shares during the period. BNP Paribas Arbitrage SNC lifted its stake in Bausch Health Companies by 17,200.6% in the first quarter. BNP Paribas Arbitrage SNC now owns 3,016,183 shares of the company’s stock valued at $24,431,000 after purchasing an additional 2,998,749 shares during the last quarter. Barclays PLC grew its holdings in Bausch Health Companies by 198.5% during the second quarter. Barclays PLC now owns 954,226 shares of the company’s stock valued at $7,633,000 after purchasing an additional 634,551 shares during the period. Finally, Mach 1 Financial Group LLC purchased a new stake in Bausch Health Companies in the first quarter worth $15,148,000. 74.56% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Bausch Health Companies
In other Bausch Health Companies news, EVP Seana Carson sold 6,685 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $8.28, for a total value of $55,351.80. Following the transaction, the executive vice president now directly owns 385,213 shares in the company, valued at approximately $3,189,563.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 13.75% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
Bausch Health Companies Price Performance
NYSE:BHC traded up $0.08 during mid-day trading on Monday, hitting $6.98. 551,924 shares of the stock traded hands, compared to its average volume of 3,638,228. The business’s 50-day moving average price is $7.60 and its 200 day moving average price is $7.90. The company has a quick ratio of 0.89, a current ratio of 1.20 and a debt-to-equity ratio of 74.20. The company has a market cap of $2.52 billion, a PE ratio of -2.61 and a beta of 0.98. Bausch Health Companies Inc. has a 12-month low of $5.57 and a 12-month high of $10.23.
Bausch Health Companies Profile
Bausch Health Companies Inc operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
- Five stocks we like better than Bausch Health Companies
- Space Investment: How to Invest in Space Exploration
- Plan to own one retailer? Make it this one
- Trading Stocks: RSI and Why it’s Useful
- Target these 3 hot retail stocks for Black Friday deals
- ETF Screener: Uses and Step-by-Step Guide
- Dell Technologies breaks out, riding high on AI
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.